85 -2 (40) 2022 — Kholov G.A., Djuraeva N.O., — IMPACT OF PULMONARY HYPERTENSION ON THE COURSE AND PROGNOSIS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
IMPACT OF PULMONARY HYPERTENSION ON THE COURSE AND PROGNOSIS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Kholov G.A., Bukhara Regional Multidisciplinary Clinical Center, Uzbekistan
Djuraeva N.O., Bukhara Regional Multidisciplinary Clinical Center, Uzbekistan
Safayev.B.B Bukhara Regional Multidisciplinary Clinical Center, Uzbekistan
Resume
Chronic obstructive pulmonary disease (COPD) is one of the main causes of chronic morbidity and mortality worldwide [1,2]. The presence of pulmonary hypertension (PH) in COPD is associated with an increase in mortality, the risk of repeated hospitalizations, and an increase in healthcare costs for the treatment of this category of patients [3, 4]. PH in COPD is more often mild to moderate [5,6], but some patients have severe PH that is “disproportionate” to the degree of airflow limitation [6].
Keywords: chronic obstructive pulmonary disease, pulmonary hypertension, obstruction, predictors.
First page
435
Last page
439
For citation: Kholov G.A., Djuraeva N.O.,Safayev.B.B IMPACT OF PULMONARY HYPERTENSION ON THE COURSE AND PROGNOSIS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE //New Day in Medicine 2(40)2022 435-439 https://clck.ru/eRfpo
LIST OF REFERENCES:
- Adnot S., Samoyeau .R, Weitzenblum E. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. //Blood Press Suppl. 1995;3:47-57. PMID: 8535542.
- Brijker F., Heijdra Y.F., van den Elshout F.J., Folgering H.T. Discontinuation of furosemide decreases PaCO2 in patients with COPD. Chest 2002;121:377–382
- Burger C.D. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD. 2009 Apr; 6(2):137-44. doi: 10.1080/15412550902754252. PMID: 19378227.
- Safoev B.B., Boltaev T.SH., Latipov O.Z. Results of development of a new treatment method patients with panarizations // Annals of the Romanian Society for Cell Biology. Romania. – 2021, Vol. 25, Issue 4, 2021, Pages. 1838 – 1846.
- Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. //Eur Respir J 2004;23:932–946.
- Clini E., Cremona G., Campana M., et al. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment. //Am J Respir Crit Care Med 2000; 162:446–450.
- Chazova I.E., Avdeev S.N., Tsareva N.A., et al. Clinical practice guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic archive 2014; 9: 4-23. (In Russ.) [Чазова И. Е., Авдеев С. Н., Царева Н. А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив 2014; 9: 4-23.]
- Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. //Am. J. Respir. Crit. Care Med 2005; 172: 189-94. DOI: 10.1164/rccm.200401-006OC.
- Galiè N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), //International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J 2016; 37 (1): 67-119. DOI: 10.1093/eurheartj/ehv317.
- Neklyudova G.V., Avdeev S.N., Baymakhanova G.E. Chronic obstructive pulmonary disease and pulmonary hypertension: brain natriuretic peptide as a marker of pulmonary hypertension. //Pulmonology 2013; 3: 31-5. (In Russ.)
- Kessler R., Oswald-Mammosser M. Does lung volume reduction surgery compromise the pulmonary circulation? //Am. J. Respir. Crit. Care Med 1999; 160: 1429-30. DOI: 10.1164/ ajrccm.160.4.16040_3.